Navigation Links
Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the,American Association of Cancer Research Annual Meeting in Los,Angeles

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that its founder, Chiang Li, MD, will present a scientific poster on Cequent's proprietary TransKingdom RNA interference (tkRNAi(TM)) technology at the 2007 annual meeting of the American Association of Cancer Research (AACR). Co-inventor, Johannes Fruehauf, MD, PhD, of Beth Israel Deaconess Medical Center/Harvard Medical School, will also present at the centennial meeting, which will take place April 14 to 18, 2007, at the Los Angeles Convention Center.

The poster presentation, "Bacteria deliver RNA interference in vitro and in vivo for cancer therapy: tkRNAi," is scheduled for Tuesday, April 17, 2007, from 1 to 5 pm in the exhibit hall.

About tkRNAi(TM)- TransKingdom RNA Interference

RNA interference (RNAi) holds great promise for the development of novel therapies based on its high specificity and potency. One major difficulty impeding the wider development of RNAi-based therapies, however, is the need to deliver the molecules triggering RNAi (short interfering RNA) into the target cells and diseased tissues. Cequent's tkRNAi technology offers an elegant "Trojan horse" solution to the delivery problem; nonpathogenic bacteria are modified to produce and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. This method, which has been shown to induce gene silencing and therapeutic effects in multiple model systems, including live animals, forms the basis for Cequent's pipeline of clinical drug candidates.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases - from inflammatory diseases to cancer - based on the
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/1/2008)...Dec. 1 Vical Incorporate... a $1.0 million milestone payment from Merck &...a Phase I clinical trial of an investigational pla...ine is based on Vical,s DNA gene delivery technolo...ase (hTERT). hTERT is the subject of separate lice...
(Date:11/28/2008)...Z, Germany, November 28 German bio...rship in specialized HIV monitoring and,AIDS pati...ing countries. In,the year 2008, 2.5 million pati...robust and highly affordable "CyFlow" system, supp...with HIV/AIDS. Due to introduction of the,Partec ...
(Date:11/26/2008)...Minn., Nov. 26 Children...t significantly increased risk of developing menta...s of a Mayo Clinic study published this month in ...Academy of Pediatrics. , , The retrospectiv...ts with strabismus (misaligned eyes) and compared ...
(Date:11/25/2008)...reness can improve recovery , , Audio and W...ilable on the Mayo Clinic News Blog. Please see th..., ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswi...oke patients don,t think they,re having a stroke -... their condition worsens. The findings appear in t...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3IOS Press congratulates IPCC with Nobel Peace Prize 1518 1Group Seeks Refinement of Knee Arthritis Treatment Guidelines 7942 1Group Seeks Refinement of Knee Arthritis Treatment Guidelines 7942 2DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program 2116 1DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program 2116 2DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program 2116 3Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference 2114 1Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference 2114 2
...2, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:C...tious disease and dermatology, today announced tha...onstrated virtually no biofilm,formation in a 21 d...eated with Ceragenins,were soaked daily in a phosp...heter. At day 21, the catheters were challenged wi...
..., 2007: Progen Industries Limited,(ASX: PGL; NASDA...se II liver cancer data has been accepted for late...ation for the Study of the Liver,(EASL). Progen wi...ncer trial at the American Association for Cancer ...ation of having final data fully analysed and read...
Other Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:12/2/2008)... Fellow occupants can help keep driving safe, rese...y News) -- Drivers talking on a cell phone are mor...were speaking with a friend sitting next to them i...s basically a process of joint attention, so when ...ienced as a driver, that person actually understan...
(Date:12/2/2008)... With new naming structure, Kessler Foundation con...disabilities , , WEST ORANGE, N.J.Dec. 2 /P...rting people with physical disabilities, Henry H. ...on,s new name -- Kessler Foundation. The Foundatio...ions to Kessler Foundation Research Center and Kes...
(Date:12/2/2008)... -Survey Reveals Nearly Half Have Skipped Medical ..., Dec. 2 A new survey r...rce Center (NWHRC) highlights another troubling as...ave failed to seek health care for themselves or t...te that many women say their health has gotten wor...
(Date:12/2/2008)... At Least 10 New Cellular Therapies Will Launch Ov...ision Resources , , WALTHAM, Mass., Dec. 2 ...ld,s leading research and advisory firms for pharm...llular therapies drug market will experience robus..., reaching $1.5 billion in 2017. According to the ...
Breaking Medicine News(10 mins):Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4Health News:Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017 2
...(SAD) is not all that well understood, but is beli...inter months. Winter depression involves suffering...he days get longer and nights get shorter. Other S...h carbohydrate foods, and sleeping for longer than...
...a patient, a two-month-old baby with white blood! ...ase caused due to a deficiency of lipoprotein lipa...ion children. Doctors said that the baby was broug...ool. On detection the baby, a boy child, was found...
...olet rays, has always been said to be bad for one'... has shown that even moderate sun exposure can res...eadliest form of skin cancer. Exposure to sun has ...r, but the link between sun exposure and melanoma,...
... there is a metabolic threshold that occurs in you...tivity becomes deleterious for lumbar bone mineral...he researchers, over a 10-year period, investigate...sical activity and LBMD in 225 men and 241 women. ...
Other Medicine News:
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Small, comes in a compact carrying case, carrying pouch included.
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure.
Medicine Products: